Top

Published in:

01-09-2016 | Clinical Trials (S Hurvitz, Section Editor)

Screening for Cognitive Impairment Associated with Chemotherapy for Breast Cancer

Authors: Diane F. Morean, Leora R. Cherney

Published in: Current Breast Cancer Reports | Issue 3/2016

Abstract

At least 20 % of women treated with chemotherapy for breast cancer experience some form of cognitive decline. Recent recommendations call for clinicians to screen cognitive abilities. Screening of factors that can contribute to cognitive impairment is also currently recommended. We describe a battery of free, online, self-report surveys that would take approximately 30 min to complete in the context of an overall functional assessment of wellness. Key physical characteristics to be screened include fatigue and insomnia. Significant psychological characteristics include distress, depression, and anxiety. Fundamental social characteristics include basic needs, workplace issues, and interpersonal well-being. Systematic screening that could be completed in the clinic waiting room or during chemotherapy infusion is an important first step towards more holistic patient care that addresses cognitive side effects, just as physical side effects of treatment are routinely addressed.

World Health Organization. Cancer: fact sheet 297. 2015. Retrieved from http://www.who.int/mediacentre/factsheets/fs297/en/

American Cancer Society. Global cancer facts and figures, 2^nd edition. 2008. Retrieved from http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf

Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2015;65:5–29. doi:10.3322/caac.21254.CrossRefPubMed

Ahles TA, Saykin AJ. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer. 2002;3:S84–90.CrossRefPubMed

Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology. 1995;4:61–6. doi:10.1002/pon.2960040108.CrossRef

Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955–69.CrossRefPubMed

Collins B, Mackenzie J, Kyeremanteng C. Study of the cognitive effects of chemotherapy: considerations in selection of a control group. J Clin Exp Neuropsychol. 2013;35:435–44. doi:10.1080/13803395.2013.781995.CrossRefPubMed

Myers JS. Chemotherapy-related cognitive impairment: the breast cancer experience. Oncol Nurs Forum. 2012;39:E31–40. doi:10.1188/12.CrossRefPubMed

Ando-Tanabe N, Iwamitsu Y, Kuranami M, Okazaki S, Yasuda H, Nakatani Y, et al. Cognitive function in women with breast cancer receiving adjuvant chemotherapy and healthy controls. Breast Cancer. 2012;21:453–62. doi:10.1007/s12282-012-0405-7.CrossRefPubMed

10.

Andreano JM, Waisman J, Donley L, Cahill L. Effects of breast cancer treatment on the hormonal and cognitive consequences of acute stress. Psycho-Oncology. 2012;21:1091–8. doi:10.1002/pon.2006.CrossRefPubMed

11.

Berman MG, Askren MK, Jung M, Therrien B, Peltier S, Noll DC, et al. Pretreatment worry and neurocognitive responses in women with breast cancer. Health Psychol. 2014;33:222–31. doi:10.1037/a0033425.CrossRefPubMed

12.

Breckenridge LM, Bruns GL, Todd BL, Feuerstein M. Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors. Psycho-Oncology. 2012;21:43–53. doi:10.1002/pon.1860.CrossRefPubMed

13.

Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S. Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. Psycho-Oncology. 2009;18:811–21. doi:10.1002/pon.1453.CrossRefPubMed

14.

Hurria A, Somlo G, Ahles T. Renaming “chemobrain”. Cancer Investig. 2007;25:373–7. doi:10.1080/07357900701506672.CrossRef

15.

Shilling V, Jenkins V, Fallowfield J, Howell T. The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Mol Biol. 2003;86:405–12. doi:10.1016/j.jsbmb.2003.07.001.CrossRefPubMed

16.

Butow PN, Phillips F, Schweder J, White K, Underhill C, Goldstein D. Psychosocial well-being and supportive care needs of cancer patients living in urban and rural/regional areas: a systematic review. Support Care Cancer. 2012;20:1–22. doi:10.1007/s00520-011-1270-1.CrossRefPubMed

17.

Hendren S, Chin N, Fisher S, Winters P, Griggs J, Mohile S, et al. Patients’ barriers to receipt of cancer care, and factors associated with needing more assistance from a patient navigator. J Natl Med Assoc. 2011;103:701–10. doi:10.1016/S0027-9684(15)30409-0.CrossRefPubMedPubMedCentral

18.•

Wagner LI, Spiegel D, Pearman T. Using the science of psychosocial care to implement the new American College of Surgeons commission on cancer distress screening standard. J Natl Compr Cancer Netw. 2013;1:214–21. This focused review provides practical information on implementing screening standards into routine breast cancer treatment.

19.

Boykoff N, Moieni M, Subramamian SK. Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv. 2009;3:223–32. doi:10.1007/s11764-009-0098-x.CrossRefPubMedPubMedCentral

20.

Bower JE. Behavioral symptoms in patients with breast cancer and survivors. J Clin Oncol. 2008;26:768–77. doi:10.1200/JCO.2007.14.3248.CrossRefPubMedPubMedCentral

21.

Vichaya EG, Chiu GS, Krukowski K, Lacourt TE, Kavelaars A, Dantzer R, et al. Review article: mechanisms of chemotherapy-induced behavioral toxicities. Front Neurosci. 2015;9:131. doi:10.3389/fnins.2015.00131.CrossRefPubMedPubMedCentral

22.

Abraham J, Haut MW, Moran MT, Filburn S, Lemiuex S, Kuwabara H. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer. 2008;8:88–91. doi:10.3816/CBC.2008.n.007.CrossRefPubMed

23.

de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, Caan M, Douaud G, et al. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp. 2012;33:2971–83. doi:10.1002/hbm.21422.CrossRefPubMed

24.

Deprez S, Amant F, Smeets A, Peeters R, Leemans A, Van Hecke W, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012;30:274–81. doi:10.1200/JCO.2011.36.8571.CrossRefPubMed

25.

Silverman DH, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat. 2007;103:303–11. doi:10.1007/s10549-006-9380-z.CrossRefPubMed

26.••

Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. J Clin Oncol. 2016;34:611–35. doi:10.1200/JCO.2015.64.3809. This ASCO special article provides recommendations to assist primary care and other clinicians in the care of breast cancer survivors, including assessment and management of cognitive impairment and contributing factors of cognitive impairment. CrossRefPubMed

27.••

American College of Surgeons Commission on Cancer (2016). Cancer program standards: ensuring patient-centered care manual, 2016 edition. Retrieved from https://www.facs.org/~/media/files/quality%20programs/cancer/coc/2016%20coc%20standards%20manual_interactive%20pdf.ashx. This manual describes CoC accreditation requirements including psychosocial distress screening and navigation.

28.

Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997;15:974–86.PubMed

29.

Wagner L, Sweet J, Butt Z, Lai J, Cella D. Measuring patient self-reported cognitive function: development of the Functional Assessment of Cancer Therapy–Cognitive Function instrument. J Support Oncol. 2009;7:W32–9.

30.

Dumas JA, Makarewicz J, Schaubhut GJ, Devins R, Albert K, Dittus K, et al. Chemotherapy altered brain functional connectivity in women with breast cancer: a pilot study. Brain Imaging Behav. 2013;7:524–32. doi:10.1007/s11682-013-9244-1.CrossRefPubMed

31.

López Zunini RA, Scherling C, Wallis N, Collins B, MacKenzie J, Bielaiew C, et al. Differences in verbal memory retrieval in breast cancer chemotherapy patients compared to healthy controls: a prospective fMRI study. Brain Imaging Behav. 2013;7:460–77. doi:10.1007/s11682-012-9213-0.CrossRefPubMed

32.

Herrera C, Chambon C, Michel BF, Paban V, Alescio-Lautier B. Positive effects of computer-based cognitive training in adults with mild cognitive impairment. Neuropsychologia. 2012;50:1871–81. doi:10.1016/j.neuropsychologia.2012.04.012.CrossRefPubMed

33.

Conroy SK, McDonald BC, Ahles TA, West JD, Saykin AJ. Chemotherapy-induced amenorrhea: a prospective study of brain activation changes and neurocognitive correlates. Brain Imaging Behav. 2013;7:491–500. doi:10.1007/s11682-013-9240-5.CrossRefPubMed

34.

Downie FP, Mar Fan HG, Houédé-Tchen N, Yi Q, Tannock IF. Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psychooncology. 2006;15:921–30. doi:10.1002/pon.1035.CrossRefPubMed

35.

Eberling JL, Wu C, Tong-Turnbeaugh R, Jagust WJ. Estrogen- and tamoxifen-associated effects on brain structure and function. Neuroimage. 2004;21:364–71. doi:10.1016/j.neuroimage.2003.08.037.CrossRefPubMed

36.

Evangelista AL, Santos EM. Cluster of symptoms in women with breast cancer treated with curative intent. Support Care Cancer. 2012;20:1499–506. doi:10.1007/s00520-011-1238-1.CrossRefPubMed

37.

Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology. 2004;1:61–66.0. doi:10.1002/pon.709.CrossRef

38.

Lyon DE, Cohen R, Chen H, Kelly DL, Starkweather A, Ahn H et al. The relationship of cognitive performance to concurrent symptoms, cancer- and cancer-treatment-related variables in women with early-stage breast cancer: a 2-year longitudinal study. J Cancer Res Clin Oncol. 2016, 1-14. doi: 10.1007/s00432-016-2163-y

39.

Pinto AC, de Azambuja E. Improving quality of life after breast cancer: dealing with symptoms. Maturitas. 2011;70:343–8. doi:10.1016/j.maturitas.2011.09.008.CrossRefPubMed

40.

Pullens MJ, De Vries J, Van Warmerdam LJ, Van De Wal MA, Roukema JA. Chemotherapy and cognitive complaints in women with breast cancer. Psychooncology. 2013;22:1783–9. doi:10.1002/pon.3214.CrossRefPubMed

41.

Reid-Arndt SA, Yee A, Perry MC, Hsieh C. Cognitive and psychological factors associated with early posttreatment functional outcomes in breast cancer survivors. Psychosoc Oncol. 2009;27:415–34. doi:10.1080/07347330903183117.CrossRef

42.

Jacobsen PB, Hann DM, Azzarello LM, Horton J, Balducci L, Lyman GH. Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symp Manag. 1999;18:233–42.CrossRef

43.

Mock V, Atkinson A, Barsevick A, Cella D, Cimprich B, Cleeland C, et al. NCCN Practice guidelines for cancer-related fatigue. Oncology. 2000;14:151–61.PubMed

44.

de Jong N, Courtens AM, Abu-Saad HH, Schouten HD. Fatigue in patients with breast cancer receiving adjuvant chemotherapy: a review of the literature. Cancer Nurs. 2002;25:283–97.CrossRefPubMed

45.

Sitzia J, Huggins L. Side effects of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy for breast cancer. Cancer Pract. 1998;6:13–21. doi:10.1046/j.1523-5394.1998.1998006013.x.CrossRefPubMed

46.

Jacobsen PB, Garland LL, Booth-Jones M, Donovan KA, Thors CL, Winters E, et al. Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. J Pain Symptom Manag. 2004;28:7–18. doi:10.1016/j.jpainsymman.2003.11.002.CrossRef

47.

National Heart Lung and Blood Institute. What causes anemia? 2012. Retrieved from http://www.nhlbi.nih.gov/health/health-topics/topics/anemia/causes

48.

Smith E, Lai JS, Cella D. Building a measure of fatigue: the Functional Assessment of Chronic Illness Therapy Fatigue Scale. PMR. 2010;2:359–63. doi:10.1016/j.pmrj.2010.04.017.CrossRef

49.

Bastien CH, VallieÁres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2:297–307. doi:10.1016/S1389-9457(00)00065-4.CrossRefPubMed

50.

Sateia MJ, Lang BJ. Sleep and cancer: recent developments. Curr Oncol Rep. 2008;10:309–18.CrossRefPubMed

51.

Airaksinen E, Larsson M, Lundberg I, Forsell Y. Cognitive functions in depressive disorders: evidence from a population-based study. Psychol Med. 2004;34(1):83–91.CrossRefPubMed

52.

Airaksinen E, Larsson M, Forsell Y. Neuropsychological functions in anxiety disorders in population-based samples: evidence of episodic memory dysfunction. J Psychiatr Res. 2005;39:207–14. doi:10.1016/j.jpsychires.2004.06.001.CrossRefPubMed

53.

Fann JR, Thomas-Rich AM, Katon WJ, Cowley D, Pepping M, McGregor BA, et al. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry. 2008;30:112–26. doi:10.1016/j.genhosppsych.2007.10.008.CrossRefPubMed

54.

Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12:160–74. doi:10.1016/S1470-2045(11)70002-X.CrossRefPubMed

55.

Lovibond SH, Lovibond PF. Manual for the depression anxiety stress scales. 2nd ed. Sydney: Psychology Foundation; 1995.

56.

Bauer A. Cancer.net, Spotlight on: oncology social workers–Part I, a Q&A. 2014. Retrieved from http://www.cancer.net/blog/2014-04/spotlight-oncology-social-workers-%E2%80%93-part-i-qa

57.

Web Finance Inc. Work environment. 2014. Retrieved from http://www.businessdictionary.com/definition/work-environment.html

58.

Morean DF, O’Dwyer L, Cherney LR. Therapies for cognitive deficits associated with chemotherapy for breast cancer: a systematic review. Arch Phys Med Rehabil. 2015;96:1880–97.CrossRefPubMed

Title: Screening for Cognitive Impairment Associated with Chemotherapy for Breast Cancer
Authors: Diane F. Morean
Leora R. Cherney
Publication date: 01-09-2016
Publisher: Springer US
Published in: Current Breast Cancer Reports / Issue 3/2016
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI: https://doi.org/10.1007/s12609-016-0219-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

Physician and Patient Barriers to Breast Cancer Preventive Therapy

Aromatase Inhibitor-Associated Arthralgia: How Big Is the Problem and What Can Be Done?

Reducing the Risk of Breast Cancer Recurrence: an Evaluation of the Effects and Mechanisms of Diet and Exercise

Update on Breast Cancer Risk Reduction Therapy

Current Approach to Breast Cancer Risk Reduction for Women with Hereditary Predispositions to Breast Cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer